More Than $11 Million Has Been Spent Advertising Invokana in Medical Journals Through Q2 2014

by Client Services

Invokana is the most advertised drug products in professional health journals through Q2 2014.  Through June, more than $11 million has been spent to advertise this product, which treats Type 2 Diabetes, according to Kantar Media. Brintellix, an antidepressant, ranks second by both dollars and pages.

Top 5 Print Ad Drugs (Dollars): June 2014

#1 Invokana – $11 MM (+137%)

#2 Brintellix Tablets – $7 MM (N/A)

#3 Fetzima - $5 MM (N/A)

#4 Xarelto - $4 MM (-50%)

#5 Belviq (Lorcaserin HCI) IV – $4 MM (N/A)

The percentage changes compare June 2014 to that same time period in 2013. For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.